Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00113399 · OUTCOME

Overall Survival

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery · Source last updated 2013-07-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Date of death or last follow-up

Analysis population: This study terminated early with 15 subjects out of 240 subjects accrued, therefore no analyses were performed.

Groups in this outcome

Re-irradiation Plus Concurrent Chemotherapy

Radiation Therapy on weeks 1, 3, 5, and 7 1.5 Gy/fx, twice daily x 5 days, 40 fractions, for a total dose of 60 Gy Chemotherapy (cisplatin/paclitaxel) on weeks 1, 3, 5, and 7 G-CSF on weeks 2, 4, 6, and 8

Chemotherapy Alone

Select from one of the three standard chemotherapy regimens: cisplatin/5-FU; cisplatin/paclitaxel; cisplatin/docetaxel

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Re-irradiation Plus Concurrent Chemotherapy0
Chemotherapy Alone0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    Radiation Therapy on weeks 1, 3, 5, and 7 1.5 Gy/fx, twice daily x 5 days, 40 fractions, for a total dose of 60 Gy Chemotherapy (cisplatin/paclitaxel) on weeks 1, 3, 5, and 7 G-CSF on weeks 2, 4, 6, and 8
    id
    OG000
    title
    Re-irradiation Plus Concurrent Chemotherapy
  2. description
    Select from one of the three standard chemotherapy regimens: cisplatin/5-FU; cisplatin/paclitaxel; cisplatin/docetaxel
    id
    OG001
    title
    Chemotherapy Alone
population Description
This study terminated early with 15 subjects out of 240 subjects accrued, therefore no analyses were performed.
reporting Status
POSTED
time Frame
Date of death or last follow-up
title
Overall Survival
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice